VSV/NDV hybrid virus for oncolytic therapy of cancer

Oncolytic virotherapy for cancer has emerged as a novel and promising therapeutic approach to replace standard cancer therapies, which often provide limited efficacy at the cost of unpleasant or severe side effects. Here, a novel VSV/NDV hybrid virus was engineered that combines the advantages of both vesicular stomatitis virus (VSV) and Newcastle disease virus (NDV) vectors, while the safety concerns of both are eliminated.

Further information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.